Every 10-Q that SBC Medical Group Holdings Incorporated (SBC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SBC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SBC filings page.
SBC Medical Group Holdings Incorporated reported solid results for the quarter ended June 30, 2026. Total revenues were $49.19 million, up from $43.36 million a year earlier, driven mainly by related-party revenues. Quarterly income from operations rose to $18.96 million from $14.55 million, and net income attributable to the company increased to $10.69 million from $2.46 million, with basic and diluted EPS of $0.10.
For the first six months of 2026, total revenues were $92.25 million versus $90.69 million in 2025, while net income attributable to the company was $22.00 million compared with $23.96 million. Operating cash flow improved markedly, moving from a use of $6.41 million in the prior-year period to positive cash provided of $31.74 million. Cash and cash equivalents increased to $184.31 million as of June 30, 2026, against total bank and other borrowings of $37.75 million, supporting a total asset base of $406.66 million and stockholders’ equity of $279.92 million.
The company recorded a $0.57 million loss from its equity method investment in OT Midco and a significant foreign currency translation loss of $9.57 million, which reduced accumulated other comprehensive income. During the quarter, SBC deconsolidated its variable interest entity AMM; the CEO’s repayment of AMM’s obligations generated a $3.65 million deemed capital contribution, boosting additional paid-in capital. Management also introduced two reportable segments (SBC core and Waqoo) and continues to highlight heavy reliance on a small number of major customers.
SBC Medical Group Holdings reported first-quarter 2026 total revenue of $43.1 million, down from $47.3 million a year earlier, as related-party revenues softened while third-party revenues grew. Gross profit declined to $30.3 million from $37.7 million, reflecting higher cost of revenues.
Income from operations fell to $17.7 million from $24.2 million. Net income attributable to SBC decreased to $11.3 million versus $21.5 million, and basic and diluted EPS declined to $0.11 from $0.21, partly because the prior-year period included a sizable gain on redemption of life insurance policies.
Despite lower earnings, operating cash flow strengthened to $9.2 million from $1.9 million, helped by working capital movements and lower income tax payments. Cash and cash equivalents rose to $167.3 million as of March 31, 2026, and total assets reached $388.0 million with total liabilities of $117.6 million. Stockholders’ equity increased to $270.4 million. Weighted average shares outstanding were 102,576,943 for the quarter, and net income included modest non-controlling interest allocations.
SBC Medical Group Holdings (SBC) reported Q3 2025 results. Total revenues were $43,353,235, down from $53,084,883 a year ago, reflecting lower related‑party revenue. Net income was $12,824,636 versus $2,832,894, aided by $2,526,035 of other income and lower operating expenses. Basic and diluted EPS were $0.12 on 102,642,634 weighted average shares.
For the nine months, total revenues were $134,040,783 versus $160,995,005, with net income of $36,785,322 versus $40,075,054. Operating cash flow was $(27,295,426), driven by working capital and related‑party movements; cash and cash equivalents were $127,431,318. The company repurchased common stock, increasing treasury stock to 1,304,308 shares at a cost of $7,749,997. Intangible assets rose to $23,302,796, and long‑term loans increased to $18,078,324. Cryptocurrencies were $570,286, with a $34,404 fair value gain recorded.
Shares outstanding were 102,576,943 as of October 31, 2025.
SBC Medical Group Holdings Incorporated reported consolidated assets of $315.3 million at June 30, 2025, up from $266.1 million a year earlier, driven by a cash balance of $152.7 million versus $125.0 million at December 31, 2024. For the six months ended June 30, 2025 the company recorded total revenues of $90.69 million, down from $107.91 million a year earlier, with related-party revenues comprising the majority at $84.20 million. Gross profit for the six-month period was $67.74 million and income from operations was $38.76 million, both lower year-over-year.
Net income attributable to SBC for the six months was $23.96 million ($0.23 per share), down from $37.24 million ($0.40 per share). Operating cash flow was an outflow of $6.41 million, offset by investing proceeds of $15.40 million largely from life insurance redemptions and financing inflows of $6.90 million, leaving ending cash higher. Key balance-sheet items include finance lease receivables of $22.33 million, long-term investments of $3.59 million, long-term investments in related MCs of $19.38 million, and 5 Bitcoins held at $535,882 fair value.